Evidence map›Paper›PMID 36877518›Full record

ArticleJAMA network open2023

Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital.

Lauren G Santos, Tatyana Buzdnitskaya, Bradley A Rolf, William Souza, Mark Sienko, Jose Alberto Ruiz-Bonilla, Binay Shah, Patrick Jewell, Lindsay Jensen, Martha Horike-Pyne and 5 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Lauren G SantosDepartment of Medicine, University of Washington, Seattle.
Tatyana BuzdnitskayaOlympic Medical Cancer Center, Sequim, Washington.
Bradley A RolfDepartment of Medicine, University of Washington, Seattle.
William SouzaOlympic Medical Cancer Center, Sequim, Washington.
Mark SienkoOlympic Medical Cancer Center, Sequim, Washington.
Jose Alberto Ruiz-BonillaOlympic Medical Cancer Center, Sequim, Washington.
Binay ShahOlympic Medical Cancer Center, Sequim, Washington.
Patrick JewellOlympic Medical Cancer Center, Sequim, Washington.
Lindsay JensenOlympic Medical Cancer Center, Sequim, Washington.
Martha Horike-PyneDepartment of Medicine, University of Washington, Seattle.
Jo Ann ElrodClinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington.
Jennie CrewsDepartment of Medicine, University of Washington, Seattle.
Mercy LaurinoClinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington.
Kevin Austin WeeksOlympic Medical Cancer Center, Sequim, Washington.
Marianne E Dubard-GaultDepartment of Medicine, University of Washington, Seattle.
Olympic Medical Center · USUniversity of Washington · USCancer Genetics (United States) · USFred Hutch Cancer Center · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

Background: Patients with cancer seen in rural and underserved areas disproportionately face barriers to access genetic services. Genetic testing is critical to inform treatment decisions, for early detection of another cancer, and to identify at-risk family members who may benefit from screening and prevention. Objective: To examine medical oncologists' genetic testing ordering trends for patients with cancer. Design, Setting, and Participants: This prospective quality improvement study was performed in 2 phases over 6 months between August 1, 2020, and January 31, 2021, at a community network hospital. Phase 1 focused on observation of clinic processes. Phase 2 incorporated peer coaching from cancer genetics experts for medical oncologists at the community network hospital. The follow-up period lasted 9 months. Main Outcomes and Measures: The number of genetic tests ordered was compared between phases. Results: The study included 634 patients (mean [SD] age, 71.0 [10.8] years [range, 39-90 years]; 409 women [64.5%]; 585 White [92.3%]); 353 (55.7%) had breast cancer, 184 (29.0%) had prostate cancer, and 218 (34.4%) had a family history of cancer. Of the 634 patients with cancer, 29 of 415 (7.0%) received genetic testing in phase 1, and 25 of 219 (11.4%) received genetic testing in phase 2. Of the 29 patients who received testing in phase 1, 20 (69.0%) had germline genetic testing; 23 of 25 patients (92.0%) had germline genetic testing in phase 2. Uptake of germline genetic testing increased by 23.0% between phases, but the difference was not statistically significant (P = .06). Uptake of germline genetic testing was highest among patients with pancreatic cancer (4 of 19 [21.1%]) and ovarian cancer (6 of 35 [17.1%]); the National Comprehensive Cancer Network (NCCN) recommends offering genetic testing to all patients with pancreatic cancer and ovarian cancer. Conclusions and Relevance: This study suggests that peer coaching from cancer genetics experts was associated with an increase in ordering of genetic testing by medical oncologists. Efforts made to (1) standardize gathering of personal and family history of cancer, (2) review biomarker data suggestive of a hereditary cancer syndrome, (3) facilitate ordering tumor and/or germline genetic testing every time NCCN criteria are met, (4) encourage data sharing between institutions, and (5) advocate for universal coverage for genetic testing may help realize the benefits associated with precision oncology for patients and their families seeking care at community cancer centers.

Indexed as

MentoringOvarian NeoplasmsPancreatic NeoplasmsPhysiciansAgedCommunity NetworksFemaleGenetic ServicesHospitals, CommunityHumansMalePrecision MedicineProspective Studies

Identifiers

PMID36877518
PMCPMC9989894
OpenAlexW4323294257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.